ABSTRACT
BACKGROUND Pulmonary arterial hypertension (PAH) is a rare, progressive vasculopathy with significant cardiopulmonary morbidity and mortality. The disease is caused by both genetic and environmental factors, with genetic variants in at least 27 genes displaying putative evidence for disease causality. Genetic testing is currently recommended for adults diagnosed with heritable or idiopathic PAH, and all children diagnosed with PAH. However, testing panels vary in the number and list of genes included, and exome/genome sequencing data may reveal variants in genes with varying levels of evidence for a relationship with PAH.
METHODS An international panel of clinical and scientific experts in PAH was formed to perform an evidence-based review of heritable and idiopathic PAH gene-disease relationships. The panel performed literature searches and applied a semi-quantitative scoring system developed by the NIH Clinical Genome Resource to classify the relative strength of PAH gene-disease relationships based on genetic and experimental evidence.
RESULTS Of twenty-seven genes curated, twelve genes (BMPR2, ACVRL1, ATP13A3, CAV1, EIF2AK4, ENG, GDF2, KCNK3, KDR, SMAD9, SOX17, and TBX4) were classified as having definitive evidence for causal effects of variants. Three genes, ABCC8, GGCX, and TET2, were classified as having moderate evidence. Six genes (AQP1, BMP10, FBLN2, KLF2, KLK1, and PDGFD) were classified as having limited evidence, and TOPBP1 was classified as having no known PAH relationship. Some of the recently identified genes with moderate or limited evidence may move to a higher classification as new evidence emerges. Five genes (BMPR1A, BMPR1B, NOTCH3, SMAD1, and SMAD4) were disputed due to a paucity of genetic evidence over time.
CONCLUSIONS Evidence-based classification of PAH gene-disease relationships indicates that twelve genes have definitive evidence for causal effects of variants. We recommend that genetic testing panels include all genes with definitive evidence and that caution be taken in the interpretation of variants identified in genes with moderate or limited evidence. Genes with no known evidence for PAH or disputed genes should not be included in testing panels.
What is New?
- Evidence-based PAH gene curation was performed using the NIH Clinical Genome Resource model.
- Heritable and idiopathic PAH are caused by pathogenic variants in a diverse set of genes, including genes in the TGFβ/BMP pathway, channelopathy genes, cell metabolism genes, growth factors and transcription factors.
- Four previously reported TGF-β/BMP pathway genes are disputed for a PAH gene-disease relationship.
What Are the Clinical Implications?
- All genes with definitive evidence for a PAH gene-disease relationship are strongly recommended to be included in genetic testing panels.
- Caution should be taken in clinical interpretation for genes with less than definitive or strong evidence and disputed genes or genes with no known genetic evidence for PAH should not be included in genetic testing panels.
- For undiagnosed cases, genetic reanalysis is recommended over time as new evidence for PAH gene-disease relationship is evaluated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was financially supported by grants from the National Institutes of Health (NIH; U24HG009650) and NHLBI R35HL140019 (MAA). SB is supported by an AHA predoctoral fellowship #834024. LS is supported by the Springboard Scheme Funders, namely the Academy of Medical Sciences (AMS), the Wellcome Trust, the Government Department of Business, Energy and Industrial Strategy (BEIS), the British Heart Foundation and Diabetes UK [SBF005\1115]. JT is supported by Spanish FEDER-ISCIII grant PI21/01593.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Gene curations are publicly available on the ClinGen website. Some of the curations are pending website upload (in progress).
Nonstandard Abbreviations and Acronyms
- APAH
- pulmonary arterial hypertension associated with other diseases
- ClinGen
- Clinical Genome Resource
- HPAH
- heritable pulmonary arterial hypertension
- IPAH
- idiopathic pulmonary arterial hypertension
- LGD
- likely gene-disrupting
- LOF
- loss of function
- PAECs
- pulmonary arterial endothelial cells
- PASMCs
- pulmonary arterial smooth muscle cells
- PAH
- pulmonary arterial hypertension
- RV
- right ventricular hypertrophy
- RVSP
- right ventricular systolic pressure
- SPS
- small patella syndrome
- VUS
- variant of uncertain significance
